A prospective, randomized, double-blind, placebo-controlled parallel-group dual site trial to evaluate the effects of a Bacillus coagulans-based product on functional intestinal gas symptoms
Douglas S Kalman, Howard I Schwartz, Patricia Alvarez, Samantha Feldman, John C Pezzullo, Diane R Krieger, Douglas S Kalman, Howard I Schwartz, Patricia Alvarez, Samantha Feldman, John C Pezzullo, Diane R Krieger
Abstract
Background: This randomized double blind placebo controlled dual site clinical trial compared a probiotic dietary supplement to placebo regarding effects on gastrointestinal symptoms in adults with post-prandial intestinal gas-related symptoms (abdominal pain, distention, flatulence) but no gastrointestinal (GI) diagnoses to explain the symptoms.
Methods: Sixty-one adults were enrolled (age 36.5 +/- 12.6 years; height 165.1 +/- 9.2 cm; weight 75.4 +/- 17.3 kg) and randomized to either Digestive Advantage Gas Defense Formula - (GanedenBC30 Bacillus coagulans GBI-30, 6086): n = 30; or Placebo: n = 31. Study subjects were evaluated every two weeks over a four-week period using validated questionnaires and standard biochemical safety testing. Outcome criteria of interest included change from baseline in Gastrointestinal Symptom Rating Scale (GSRS) abdominal pain, abdominal distention, flatus, and the Severity of Dyspepsia Assessment (SODA) bloating and gas subscores over four weeks of product use.
Results: Measured against the placebo, subjects in the probiotic group achieved significant improvements in GSRS abdominal pain subscore (p = 0.046) and the GSRS total score (p = 0.048), with a strong trend for improvement on the GSRS abdominal distension subscore (p = 0.061). A strong placebo effect was evident which could explain the lack of statistical significant differences between the groups for many of the efficacy variables.
Conclusion: In conclusion, the Bacillus coagulans-based product was effective in improving the quality of life and reducing gastrointestinal symptoms in adults with post prandial intestinal gas-related symptoms and no GI diagnoses.
Trial registration: ClinicalTrials.gov Identifier: NCT00881322.
References
- Savage DC. Microbial ecology of the human gastrointestinal tract. Annual Review of Microbiology. 1977;31:107–133. doi: 10.1146/annurev.mi.31.100177.000543.
- Bengmark S. Pre-, pro-, and synbiotics. Current Opinion in Clinical Nutrition and Metabolic Care. 2001;4:571–579. doi: 10.1097/00075197-200111000-00019.
- Roberfroid MB, Bornet F, Boulet C, Cummings JH. Colonic microflora: nutrition and healthL summary and conclusions of an International Life Sciences Institute (ILSI) Europe workshop held in Barcelona, Spain. Nutrition Reviews. 1995;53:127–130.
- Lichman SM. Bacterial translocation in humans. Journal of Pediatric Gastroenterol Nutrition. 2001;33:1–10. doi: 10.1097/00005176-200107000-00001.
- Guarner F, Malagelada JR. Gut flora in health and disease. The Lacent. 2003;360:512–519.
- de Vrese M, Stegelmann A, Richter B, Fenselau S, Laue C, Schrezenmeir J. Probiotics - compensation for lactase insufficiency. American Journal of Clinical Nutrition. 2001;73(Suppl):421–429.
- Bernet MF, Brassart D, Neeser JR, Servin AL. Lactobacillus acidophilus LA 2 binds to culture human intestinal cell lines and inhibits cell attachment and cell invasion by enterovirulent bacteria. Gut. 1994;35:483–489. doi: 10.1136/gut.35.4.483.
- Levri KM, Ketvertis K, Deramo M, Merestein JH, D'Amico F. Do probiotics reduce adult lactose intolerance? The Journal of Family Practice. 2005;54:613–620.
- Hun L. Original research: Bacillus coagulans significantly improved abdominal pain and bloating in patients with IBS. Postgraduate Medicine. 2009;121(2):119–124. doi: 10.3810/pgm.2009.03.1984.
- Dimenas E, Glise H, Hallerback B, Hernqvist H, Svedlund J, Wiklund I. Quality of life of patients with upper gastrointestinal symptoms: An improved evaluation of treatment regimens? Scandinavian Journal of Gastroenterology. 1993;28:681–687. doi: 10.3109/00365529309098272.
- Rabeneck L, Cook KF, Wristers K, Souchek J, Menke T, Wray NP. Soda (severity of dyspepsia assessment): A new effective outcome measure for dyspepsia-related health. Journal of Clinical Epidemiology. 2001;54:755–765. doi: 10.1016/S0895-4356(00)00365-6.
Source: PubMed